Document 0193
 DOCN  M95A0193
 TI    Should clinical freedom be constrained in the name of self-sufficiency?
 DT    9510
 AU    Schimpf K; German Haemophilia Society, Heidelberg.
 SO    Blood Coagul Fibrinolysis. 1994 Dec;5 Suppl 4:S47-9. Unique Identifier :
       AIDSLINE MED/95315444
 AB    Clinical freedom should enable a physician to decide in a free and
       unbiased manner which is the most appropriate therapy to use for a
       particular patient. In order to implement the four aims of the German
       Haemophilia Society an average of 4-4.5 units of Factor VIII per capita
       of the general population per year is needed. At present European
       countries do not produce this amount, but to reduce the consumption of F
       VIII in therapy lowers treatment levels. Until plasma collection
       services in Europe can be expanded it is necessary that the additional,
       imported, sources of plasma are available, otherwise clinical freedom
       will be curtailed.
 DE    Adult  Blood Proteins/SUPPLY & DISTRIBUTION  Child  Commerce  European
       Economic Community  Factor VIII/ADVERSE EFFECTS/ECONOMICS/ISOLATION &
       PURIF/*SUPPLY &  DISTRIBUTION  Germany  Health Policy
       Hemophilia/*THERAPY  Human  HIV Infections/PREVENTION &
       CONTROL/TRANSMISSION  *Professional Autonomy  Safety  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).